NCPA member A.J. Day represented NCPA in a June 27 meeting titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest Public Workshop,” which was held by the FDA in partnership with the Reagan-Udall Foundation. Day’s presentation focused on regulatory confusion surrounding permissible compounding of ketamine, as well as best practices for compounding as recently promoted by the Alliance for Pharmacy Compounding. For the slides from the presentation, click here (Day’s presentation is on pages 122-135).
NCPA
